Literature DB >> 20188495

Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.

Wendy M Walwyn1, Karen A Miotto, Christopher J Evans.   

Abstract

There are few pharmaceuticals superior to opiates for the treatment of pain. However, with concerns of addiction, withdrawal and questionable efficacy for all types of pain, these compounds are far from a magical panacea for pain-relief. As it is unlikely that other classes of compounds will supersede the opioids in the very near future, it is important to both optimize current opioid therapies and curb the astounding diversion of opioids from their intended analgesic use to non-medical abuse. In optimizing opioid therapeutics it is necessary to enhance the clinical awareness of the benefits of treating pain and combine this with aggressive strategies to reduce diversion for non-medical use. At the heart of the issue of opioid misuse is the role of opioid systems in the reward circuitry, and the adaptive processes associated with repetitive opioid use that manifest during withdrawal. Emerging pharmacological insights of opioid receptors will be reviewed that provide future hope for developing opioid-based analgesics with reduced addictive properties and perhaps, reduced opponent processes. In addition, with the increased understanding of nociceptive circuitry and the molecules involved in transmitting pain, new therapeutic targets have become evident that may result in effective analgesics either alone or in combination with current opioid therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188495      PMCID: PMC3072810          DOI: 10.1016/j.drugalcdep.2010.01.001

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  88 in total

Review 1.  Incentive-sensitization and addiction.

Authors:  T E Robinson; K C Berridge
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

2.  C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization.

Authors:  T Koch; S Schulz; M Pfeiffer; M Klutzny; H Schröder; E Kahl; V Höllt
Journal:  J Biol Chem       Date:  2001-05-18       Impact factor: 5.157

Review 3.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

4.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Authors:  Maria Waldhoer; Jamie Fong; Robert M Jones; Mary M Lunzer; Shiv K Sharma; Evi Kostenis; Philip S Portoghese; Jennifer L Whistler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

Review 5.  Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction.

Authors:  Bridget A Martell; Patrick G O'Connor; Robert D Kerns; William C Becker; Knashawn H Morales; Thomas R Kosten; David A Fiellin
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

6.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

Review 7.  Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.

Authors:  Laxmaiah Manchikanti; Angelie Singh
Journal:  Pain Physician       Date:  2008-03       Impact factor: 4.965

Review 8.  Ziconotide: an update and review.

Authors:  Jason A Williams; Miles Day; James E Heavner
Journal:  Expert Opin Pharmacother       Date:  2008-06       Impact factor: 3.889

9.  Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.

Authors:  Marcelo E Bigal; Daniel Serrano; Michael Reed; Richard B Lipton
Journal:  Neurology       Date:  2008-08-19       Impact factor: 9.910

10.  In vivo delta opioid receptor internalization controls behavioral effects of agonists.

Authors:  Amynah A A Pradhan; Jérôme A J Becker; Grégory Scherrer; Petra Tryoen-Toth; Dominique Filliol; Audrey Matifas; Dominique Massotte; Claire Gavériaux-Ruff; Brigitte L Kieffer
Journal:  PLoS One       Date:  2009-05-01       Impact factor: 3.240

View more
  20 in total

1.  Ubiquitination in the first cytoplasmic loop of μ-opioid receptors reveals a hierarchical mechanism of lysosomal down-regulation.

Authors:  James N Hislop; Anastasia G Henry; Mark von Zastrow
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

2.  The association between prescribed opioid use for mothers and children: a record-linkage study.

Authors:  Tomas Log; Svetlana Skurtveit; Randi Selmer; Aage Tverdal; Kari Furu; Ingeborg Hartz
Journal:  Eur J Clin Pharmacol       Date:  2012-06-09       Impact factor: 2.953

3.  RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.

Authors:  Sevasti Gaspari; Valeria Cogliani; Lefteris Manouras; Ethan M Anderson; Vasiliki Mitsi; Kleopatra Avrampou; Fiona B Carr; Venetia Zachariou
Journal:  Neuropsychopharmacology       Date:  2017-01-11       Impact factor: 7.853

Review 4.  In vivo opioid receptor heteromerization: where do we stand?

Authors:  D Massotte
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

5.  Differential Desensitization Observed at Multiple Effectors of Somatic μ-Opioid Receptors Underlies Sustained Agonist-Mediated Inhibition of Proopiomelanocortin Neuron Activity.

Authors:  Philip D Fox; Shane T Hentges
Journal:  J Neurosci       Date:  2017-08-07       Impact factor: 6.167

6.  Overview and historical perspective of four papers presented on research related to the endogenous opioid system.

Authors:  Mary Jeanne Kreek
Journal:  Drug Alcohol Depend       Date:  2010-04-18       Impact factor: 4.492

7.  How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways.

Authors:  Sebastian Schneider; Davide Provasi; Marta Filizola
Journal:  Biochemistry       Date:  2016-11-07       Impact factor: 3.162

8.  Introduction to the College on Problems of Drug Dependence special issue: contemporary advances in opioid neuropharmacology.

Authors:  Sharon L Walsh; Ellen M Unterwald; Sari Izenwasser
Journal:  Drug Alcohol Depend       Date:  2010-04-07       Impact factor: 4.492

9.  Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/β-catenin pathway.

Authors:  Sevasti Gaspari; Immanuel Purushothaman; Valeria Cogliani; Farhana Sakloth; Rachael L Neve; David Howland; Robert H Ring; Elliott M Ross; Li Shen; Venetia Zachariou
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-12       Impact factor: 11.205

10.  Newly initiated opioid treatment and the risk of fall-related injuries. A nationwide, register-based, case-crossover study in Sweden.

Authors:  Karin C Söderberg; Lucie Laflamme; Jette Möller
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.